Veriti Management LLC grew its holdings in GSK plc (NYSE:GSK – Get Rating) by 14.3% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,062 shares of the pharmaceutical company's stock after buying an additional 1,509 shares during the quarter. Veriti Management LLC's holdings in GSK were worth $525,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Cerro Pacific Wealth Advisors LLC acquired a new position in GSK in the second quarter worth about $222,000. Bell Bank raised its holdings in shares of GSK by 7.5% in the 2nd quarter. Bell Bank now owns 181,384 shares of the pharmaceutical company's stock worth $7,896,000 after buying an additional 12,681 shares in the last quarter. Herold Advisors Inc. lifted its position in shares of GSK by 4.7% during the 2nd quarter. Herold Advisors Inc. now owns 34,485 shares of the pharmaceutical company's stock worth $1,501,000 after buying an additional 1,533 shares during the period. Transform Wealth LLC boosted its stake in GSK by 2.3% in the 2nd quarter. Transform Wealth LLC now owns 149,383 shares of the pharmaceutical company's stock valued at $6,553,000 after buying an additional 3,419 shares in the last quarter. Finally, Ritholtz Wealth Management boosted its stake in GSK by 39.3% in the 2nd quarter. Ritholtz Wealth Management now owns 42,230 shares of the pharmaceutical company's stock valued at $1,838,000 after buying an additional 11,920 shares in the last quarter. 16.86% of the stock is owned by institutional investors.
Get GSK alerts:GSK Stock Down 0.6 %
NYSE:GSK opened at $28.66 on Wednesday. The stock's fifty day moving average price is $35.18 and its two-hundred day moving average price is $40.69. The company has a market cap of $58.29 billion, a price-to-earnings ratio of 9.49, a P/E/G ratio of 1.12 and a beta of 0.61. GSK plc has a 52-week low of $28.47 and a 52-week high of $46.97. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.31 and a current ratio of 1.43.
GSK (NYSE:GSK – Get Rating) last issued its quarterly earnings results on Wednesday, July 27th. The pharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.76 by $0.11. The business had revenue of $8.71 billion for the quarter, compared to analyst estimates of $9.35 billion. GSK had a return on equity of 27.84% and a net margin of 12.91%. On average, analysts anticipate that GSK plc will post 3.23 EPS for the current year.GSK Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 6th. Stockholders of record on Friday, August 19th will be paid a $0.383 dividend. This represents a $1.53 annualized dividend and a dividend yield of 5.35%. The ex-dividend date is Thursday, August 18th. This is a positive change from GSK's previous quarterly dividend of $0.35. GSK's dividend payout ratio (DPR) is 50.66%.
Analyst Upgrades and Downgrades
GSK has been the subject of a number of analyst reports. UBS Group cut their price objective on GSK from GBX 1,876 ($22.67) to GBX 1,850 ($22.35) in a report on Wednesday, July 20th. TheStreet lowered shares of GSK from a "b" rating to a "c+" rating in a research report on Monday, August 29th. StockNews.com cut shares of GSK from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, September 20th. Morgan Stanley cut their target price on shares of GSK from GBX 1,860 ($22.47) to GBX 1,550 ($18.73) in a research note on Wednesday, September 7th. Finally, AlphaValue lowered GSK to a "reduce" rating in a research report on Tuesday, July 19th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, GSK presently has an average rating of "Hold" and a consensus price target of $1,700.00.
GSK Profile
(Get Rating)
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Featured Articles
- Get a free copy of the StockNews.com research report on GSK (GSK)
- Defensive Stocks For A Volatile Market
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- Will UPS Be Next to Deliver a Warning?
- Is This the Darkest Before the Dawn for Gap Stock?
- Build A Better Tech Portfolio With Jabil Inc.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSK – Get Rating).
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.